Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.
July 07, 2022 09:30 ET
|
Sorrento Therapeutics, Inc.
Ancora Medical Inc. (“Ancora”) is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain...
Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors
July 05, 2022 14:04 ET
|
Sorrento Therapeutics, Inc.
PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE,...
Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji
June 24, 2022 15:38 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and...
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
June 14, 2022 10:33 ET
|
Sorrento Therapeutics, Inc.; Vickers Vantage Corp. I
Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout...
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
June 03, 2022 09:20 ET
|
Sorrento Therapeutics, Inc.
STI-1558, an oral SARS-CoV-2 main protease inhibitor, is specifically designed as a standalone treatment and prevention of COVID-19 without the co-administration of ritonavir as a booster for CYP3A4...
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes
June 03, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO and PALO ALTO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq:...
Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans
June 02, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Earlier this year, a national pharmacy benefit manager (PBM) moved a large percentage of its patients from not covered to covered, adding access to ZTlido for 5.5 million lives. ZTlido is now covered...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Positive Clinical Progress of A166, an Anti-HER2 ADC, in Treating Locally Advanced or Metastatic HER2-Positive Breast Cancer Patients at the ASCO 2022 Annual Meeting
June 01, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
A166 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody conjugated to Duostatin-5, a novel anti-microtubule Auristatin derivative, via a proprietary stable covalent linker.The ASCO...
Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain
May 18, 2022 09:30 ET
|
Sorrento Therapeutics, Inc.
Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4%...
Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors
May 18, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and...